If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksACC.L Regulatory News (ACC)

  • There is currently no data for ACC

Pulsar update

6 Feb 2020 07:00

RNS Number : 1294C
Access Intelligence PLC
06 February 2020
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR"). Upon the publication of this announcement, the inside information is now considered to be in the public domain for the purposes of MAR.

 

 

 

6th February 2020

ACCESS INTELLIGENCE PLC

Completion of Pulsar Accounting Review

Further to the announcement on 10 December 2019, the Board of Access Intelligence provides the following update following the completion of the review by an external firm of accountants of the accounts of the Pulsar business at closing.

In October 2019, Access Intelligence acquired the Pulsar business (comprising both Fenix Media Limited, which is incorporated in the UK, and Face US, which is incorporated in the US) from Cello Health plc ("Cello"). Following the identification of certain accounting questions on some contracts within Pulsar post acquisition, the Board of Access Intelligence commissioned an accounting review to be undertaken by independent accountants BDO.

Following completion of the BDO review, an adjustment of the previously disclosed unaudited financial results for Pulsar is required. Post this adjustment, for the year to 31 December 2018 Pulsar reported unaudited revenues of £6.8 million, gross profit of £3.8 million and an Adjusted EBITDA loss of £0.7 million. Upon acquisition by Access Intelligence, Pulsar's accounting reference period was amended. For the 11 month period to 30 November 2019, Pulsar would have had reported unaudited revenue of £5.2 million, gross profit of £2.3 million and an Adjusted EBITDA loss of £1.7 million.

Pursuant to the terms of the sale and purchase agreement signed on 2 October 2019 (the "Agreement"), and under the completion accounts reconciliation process agreed by both sides, Cello Health has agreed to pay Access Intelligence a net cash sum of £1.6m reflecting the shortfall in net assets delivered at closing versus the agreed target closing position.

In full and final settlement of any dispute under the Agreement regarding the appropriate valuation of the business, Cello Health has agreed that 4,076,238 of the consideration shares will be sold back to Access Intelligence for £1. As Access Intelligence currently does not have the requisite approvals to acquire these shares, a shareholder's meeting will be convened to obtain the necessary approval for the buy back. Upon completion of the buy back the relevant shares will be cancelled.

The post-acquisition contribution of Pulsar to Access Intelligence's consolidated financial results for the year to 30 November 2019 is expected to be revenue of £0.7 million, gross profit of £0.2 million and an Adjusted EBITDA loss of £0.5 million, prior to any acquisition accounting adjustments. The annual accounts may also be impacted by a potential non-cash write down. This is currently being discussed with the accountants and an update will be provided in due course.

This outcome of the financial analysis has no impact on the rationale for the Pulsar acquisition which is in line with a strategic ambition to strengthen capabilities in social media analysis, audience segmentation and social media marketing evaluation. Recurring revenues with Pulsar are around 70% of total revenue.

Related Party Transaction

Cello is a related party of the Company for the purposes of the AIM Rules by virtue of their status as substantial shareholders holding 10% or more or more of the Company's existing ordinary share capital.

The Board consider, having consulted with the Company's nominated adviser, finnCap, that the settlement with Cello set out above is fair and reasonable insofar as the Company's shareholders are concerned.

Commenting on the resolution of this matter, Joanna Arnold, CEO, said:

"Due to Cello Health's proactive engagement, we are pleased to have reached a swift and satisfactory resolution. The rationale for the acquisition remains unchanged and we look forward to growing the business as part of the Access Intelligence portfolio."

For further information:

Access Intelligence plc 020 3426 4024

Joanna Arnold (CEO) / Mark Fautley (CFO)

 

finnCap Limited (Nominated Adviser and Broker) 020 7220 0500

Corporate Finance - Marc Milmo / Kate Bannatyne / Matthew Radley / Kate Washington

Corporate Broking - Alice Lane / Sunila de Silva

 

About Access Intelligence

 Access Intelligence PLC is a tech innovator, delivering high quality SaaS products that address the fundamental business needs of more than 3,500 global brands in the PR, communications and marketing industries. Listed on AIM, Access Intelligence provides technology that helps organisations understand what's important to their customers and their brand as they navigate a constantly changing world of politics, news and social media. This is alongside the practical tools and information to ensure their communications are relentlessly effective in building awareness, reputation and engagement.

 The expanding portfolio includes Vuelio, the platform that helps organisations make their stories matter; ResponseSource, a network that connects media and influencers to the resources they need, fast; and Pulsar, an audience insights and social listening platform.

 

- ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FURSSIEEIESSESE
Date   Source Headline
1st Feb 20182:36 pmRNSTotal Voting Rights
29th Jan 201812:22 pmRNSHolding(s) in Company
23rd Jan 20181:58 pmRNSHolding(s) in Company
5th Jan 20184:24 pmRNSHolding(s) in Company
3rd Jan 20183:21 pmRNSHolding(s) in Company
29th Dec 20177:00 amRNSConversion of Loan Notes
21st Nov 20172:20 pmRNSHolding(s) in Company
20th Nov 20177:00 amRNSTrading Update
10th Nov 201710:26 amRNSDirectorate Change
18th Oct 20178:53 amRNSHolding(s) in Company
25th Aug 20177:00 amRNSInterim results for 6 months to 31 May 2017
31st Jul 20175:00 pmRNSTotal Voting Rights
26th Jul 201712:28 pmRNSDirector/PDMR Shareholding
25th Jul 20171:08 pmRNSHolding(s) in Company
24th Jul 201712:03 pmRNSHolding(s) in Company
24th Jul 201710:10 amRNSHolding(s) in Company
18th Jul 20177:00 amRNSSubscription to raise £1,020,000
26th May 20173:05 pmRNSResult of AGM
11th May 20176:09 pmRNSDirector/PDMR Shareholding
9th May 20174:00 pmRNSHolding(s) in Company
2nd May 20172:02 pmRNSDirectorate Change
2nd May 20177:00 amRNSFinal Results
21st Mar 20174:26 pmRNSSale of AI ControlPoint Limited
7th Feb 20172:03 pmRNSIssue of Equity
31st Jan 20179:43 amRNSHolding(s) in Company
3rd Jan 201710:21 amRNSHolding(s) in Company
28th Dec 20163:28 pmRNSExtension of Convertible Loan Notes
18th Oct 20166:00 pmRNSHolding(s) in Company
17th Aug 20167:00 amRNSUnaudited results for 6 months ended 31 May 2016
2nd Aug 20166:30 pmRNSHolding(s) in Company
4th Jul 20167:00 amRNSDisposal
9th May 20165:11 pmRNSHolding(s) in Company
5th May 20162:52 pmRNSResult of AGM
22nd Apr 20164:18 pmRNSRedemption of £0.9m of 2015 Loan Notes
20th Apr 20167:00 amRNSHolding(s) in Company
11th Apr 20167:00 amRNSPreliminary results for the y/e 30 November 2015
14th Mar 20167:00 amRNSChange of Adviser
23rd Feb 20164:54 pmRNSHolding(s) in Company
3rd Feb 20167:00 amRNSDisposal of Due North
23rd Dec 20151:03 pmRNSIssue of Equity
30th Nov 20152:20 pmRNSChange of Registered Office
25th Nov 20157:00 amRNSHolding(s) in Company
30th Oct 20158:26 amRNSHolding(s) in Company
6th Oct 20151:46 pmRNSHolding(s) in Company
1st Oct 20158:00 amRNSDirector/PDMR Shareholding
24th Aug 20157:00 amRNSInterim Results
5th Aug 20157:00 amRNSIssue of Equity
8th Jul 201511:30 amRNSHolding(s) in Company
1st Jul 20157:00 amRNSTotal Voting Rights
24th Jun 20157:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.